Kinase News and Research

RSS

Research in progress for novel protein kinase inhibitors: GEN

Biotech scientists are working on novel protein kinase inhibitors that are targeting a host of conditions ranging from atherosclerosis to neurodegenerative diseases, reports Genetic Engineering & Biotechnology News.

4 Jun 2011

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

A drug that targets a specific type of lung cancer shows a dramatic response in more than half of the people who take it. The drug, called crizotinib, has been in clinical trials since 2006, and the results from the largest group of patients to take it within the first of these clinical trials are being presented at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

ARIAD Pharmaceuticals, Inc. today announced initial clinical findings on ponatinib in patients with advanced acute myeloid leukemia (AML).

3 Jun 2011

Scientists uncover new therapeutic target that could prevent stress-related cell death

Scientists from the Florida campus of The Scripps Research Institute have uncovered a potentially important new therapeutic target that could prevent stress-related cell death, a characteristic of neurodegenerative diseases such as Parkinson's, as well as heart attack and stroke.

3 Jun 2011

Johns Hopkins researchers solve mystery of Warburg effect

It’s long been known that cancer cells eat a lot of sugar to stay alive. In fact, where normal, noncancerous cells generate energy from using some sugar and a lot of oxygen, cancerous cells use virtually no oxygen and a lot of sugar. Many genes have been implicated in this process and now, reporting in the May 27 issue of Cell, researchers at the Johns Hopkins University School of Medicine have discovered that this so-called Warburg effect is controlled.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Researchers discover new drug target that may effectively prevent onset of Huntington's disease

McMaster University researchers have discovered a new drug target that may be effective at preventing the onset of Huntington's disease, working much the same way heart medications slow the progression of heart disease and reduce heart attacks.

1 Jun 2011

Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer

Davos Life Science has today announced preliminary results of a phase I clinical trial of its Natural e3 delta-tocotrienol (Natural e3) in patients with resectable pancreatic cancer. Tocotrienols are highly potent members of the Vitamin E family that have been found by researchers to inhibit the growth and survival of various types of cancer cells.

30 May 2011

Molecular mechanism of selected autophagy elucidated

Salmonella is widely prevalent in the animal kingdom. The reason we do not suffer from severe intestinal infections very often is due to our body's defence system, which manages to digest invading bacteria. This is why, generally speaking, a healthy human being will only fall ill if he consumes more than 100.000 salmonella bacteria via a contaminated food source, such as eggs or meat.

27 May 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.

26 May 2011

Tofacitinib safe and effective for patients with rheumatoid arthritis

Results of a Phase III study presented today at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group. Significant improvements were also observed in the 5 mg BID dose.

26 May 2011

Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors

Pathway Therapeutics, Inc., a company developing novel therapeutics that target the PI3K and mTOR pathways, today announced that the FDA has accepted an IND filing for PWT33597, which allows Pathway to commence Phase 1 clinical testing.

25 May 2011

Leukemia protein plays a role in Alzheimer's disease

After decades of studying the pathological process that wipes out large volumes of memory, scientists at The Feinstein Institute for Medical Research discovered a molecule called c-Abl that has a known role in leukemia also has a hand in Alzheimer's disease.

25 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Scientists find new drug target in breast cancer

Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new treatments, they report today in the journal Nature Medicine.

23 May 2011

Tumor necrosis factor can suppress inflammation, treat rheumatoid arthritis

A new study by rheumatologists at Hospital for Special Surgery in New York has shown that a powerful pro-inflammatory protein, tumor necrosis factor, can also suppress aspects of inflammation.

23 May 2011

Researchers identify new drug resistant protein in breast cancer

Researchers have identified a new protein involved in the development of drug resistance in breast cancer which could be a target for new treatments, they report today in the journal Nature Medicine.

23 May 2011

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Silence Therapeutics plc, a leading global RNA interference therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology Annual Meeting on 06 June 2011.

19 May 2011

Pfizer seeks U.S. FDA, Japanese MHLW approval for crizotinib NDA to treat ALK-positive advanced NSCLC

Pfizer Inc. announced today that its New Drug Application for crizotinib, an oral first-in-class anaplastic lymphoma kinase inhibitor, has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration and has been filed with the Japanese Ministry of Health, Labour and Welfare.

17 May 2011

Elevated levels of cardiac troponins T or I after angioplasty linked to long-term all-cause mortality

New research shows that elevated levels of cardiac troponin T (cTnT) or I (cTnI) in patients who had angioplasty indicate a higher risk of all-cause mortality and long-term adverse events such as heart attack.

13 May 2011

Kinase News and Research

Research in progress for novel protein kinase inhibitors: GEN

Medical oncologists confirm benefits of crizotinib in ALK positive lung cancer

ARIAD's ponatinib initial Phase 1 study data on acute myeloid leukemia to be presented at ASCO 2011

Scientists uncover new therapeutic target that could prevent stress-related cell death

Johns Hopkins researchers solve mystery of Warburg effect

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Researchers discover new drug target that may effectively prevent onset of Huntington's disease

Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer

Molecular mechanism of selected autophagy elucidated

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Tofacitinib safe and effective for patients with rheumatoid arthritis

Pathway receives FDA approval to commence PWT33597 Phase 1 study in advanced solid tumors

Leukemia protein plays a role in Alzheimer's disease

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Scientists find new drug target in breast cancer

Tumor necrosis factor can suppress inflammation, treat rheumatoid arthritis

Researchers identify new drug resistant protein in breast cancer

Silence to present new Atu027 Phase I study data in advanced solid tumors at ASCO annual meeting

Pfizer seeks U.S. FDA, Japanese MHLW approval for crizotinib NDA to treat ALK-positive advanced NSCLC

Elevated levels of cardiac troponins T or I after angioplasty linked to long-term all-cause mortality

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News